Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer

Dirican, Ebubekir; Kaya, Zehra; Güllü, Gökçe; Peker, Irem; Özmen, Tolga; Güllüoğlu, Bahadır M.; Kaya, Handan; Özer, Ayşe; Akkiprik, Mustafa

doi:10.7314/apjcp.2014.15.21.9327

Cited by 13 publications

(8 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some group have also detected several different PIK3CA mutations in same sample by using next-generation sequencing and Sanger Sequencing. It is possible that one sample harvest three or two different mutations in the same gene [ 23 , 24 ]. In addition, PIK3CA mutation can coexist with KRAS, EGFR and BRAF [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

et al. 2016

View full text Add to dashboard Cite

BackgroundPhosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutations that activate the PI3K/AKT signaling pathway have been observed in several types of carcinoma and have been associated with patient prognosis. However, the significance of PIK3CA mutations in gastric cancer remains unclear. This retrospective study investigated the relationship between PIK3CA mutations and clinical outcomes in patients with gastric cancer. Additionally, we reviewed the rate of PIK3CA mutations in gastric cancer and the association between PIK3CA mutations and prognosis in human cancers.MethodsThe study included 208 patients with gastric cancer who underwent surgical resection at Kumamoto University Hospital, Japan, between January 2001 and August 2010. Mutations in PIK3CA exons 9 and 20 were quantified by pyrosequencing assays.ResultsPIK3CA mutations were detected in 25 (12 %) of the 208 patients. Ten patients had c.1634A > G (p.E545G), 10 had c.1624G > A (p.E542K), 13 had c.1633G > A (p.E545K), nine had c.3139C > T (p.H1047R), and 1 had c.3140A > G (p.H1047Y) mutations. PIK3CA mutations were not significantly associated with any clinical, epidemiologic, or pathologic characteristic. Kaplan–Meier analysis showed no significant differences in disease-free survival (log rank P = 0.84) and overall survival (log rank P = 0.74) between patients with and without PIK3CA mutations.ConclusionsMutations in PIK3CA did not correlate with prognosis in patients with gastric cancer, providing additional evidence for the lack of relationship between the two.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…What's more, HER2-enhanced tumors that likewise harbor PIK3CA changes are less receptive to blends of HER2 inhibitors (trastuzumab/lapatinib and trastuzumab/epratuzumab), adding to the prognostic and helpful importance of PIK3CA mutation testing [35,41]. PIK3CA is the most as often as possible changed quality found in BC and plays a vital role in its turn of events, incorporating a solid relationship with Oestrogen Receptor (ER) articulation and an absence of a relationship with strong actuation of the classical style PI3 K pathway [42,43]. Following the underlying disclosure of PIK3CA mutations in BC, numerous gatherings explored mutational examination to advance the information on hereditary changes that corresponded with BC's clinic pathological qualities [42].…”

Section: Pik3camentioning

confidence: 99%

“…PIK3CA is the most as often as possible changed quality found in BC and plays a vital role in its turn of events, incorporating a solid relationship with Oestrogen Receptor (ER) articulation and an absence of a relationship with strong actuation of the classical style PI3 K pathway [42,43]. Following the underlying disclosure of PIK3CA mutations in BC, numerous gatherings explored mutational examination to advance the information on hereditary changes that corresponded with BC's clinic pathological qualities [42]. In breast tumors, PIK3CA changes were reliably connected with receptor-2 (HER2)-positive tumor status of ER-positive and human epidermal development factor [44,46,48].…”

Section: Pik3camentioning

confidence: 99%

Moderate Spectrum Genes Associated With Breast Cancer

Lü

2022

AJBSR

View full text Add to dashboard Cite

“…Also, PIK3CA is one of the most commonly mutated oncogenes in several types of human cancer, including breast, colon and endometrial cancer (Cizkova et al, 2013;Dirican et al, 2016). In 2014, we aimed PIK3CA mutations in BCa investigating clinical and prognostic significances (Dirican et al, 2014). And frequency of PIK3CA mutations found 31%, should be diagnostic significance (Dirican et al, 2014).…”

mentioning

confidence: 99%

“…In 2014, we aimed PIK3CA mutations in BCa investigating clinical and prognostic significances (Dirican et al, 2014). And frequency of PIK3CA mutations found 31%, should be diagnostic significance (Dirican et al, 2014). We believe the potential of PIK3CA mutations as an important biomarker for BCa classification and the possible use of PIK3CA inhibitor as targeted therapy for BCa.…”

mentioning

confidence: 99%

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Dirican

2020

Asian Pac J Cancer Prev

Self Cite

View full text Add to dashboard Cite

Dear EditorI have read with interest the article in this journal by Patra et al., (2017) concerning BRAF, KRAS and PIK3CA mutation and sensitivity to trastuzumab in breast cancer cell line model. They evaluated trastuzumab responsiveness in breast cancer (BCa) cell lines. They showed the optimum concentration of trastuzumab to be 7 μg/well. Moreover, they detected BRAF and KRAS mutated cell line, MDA-MB-231, found the least sensitivity after being treated with trastuzumab when to the sensitivity of the PIK3CA mutated cell lines, MCF-7 and MDA-MB-361, and KRAS-BRAF-PIK3CA cell line, MDA-MB-453.Phosphatidylinositol-4,5-bisphosphate 3 kinase catalytic subunit α (PIK3CA), which is located on chromosome 3, encodes the catalytic subunit p110α of class IA phosphoinositide 3-kinase (PI3K). Also, PIK3CA is one of the most commonly mutated oncogenes in several types of human cancer, including breast, colon and endometrial cancer (Cizkova et al., 2013;Dirican et al., 2016). In 2014, we aimed PIK3CA mutations in BCa investigating clinical and prognostic significances (Dirican et al., 2014). And frequency of PIK3CA mutations found 31%, should be diagnostic significance (Dirican et al., 2014). We believe the potential of PIK3CA mutations as an important biomarker for BCa classification and the possible use of PIK3CA inhibitor as targeted therapy for BCa. Therefore, we need to increase the number of trials on the PIK3CA gene in vivo and in vitro. In the future, these trials will help to choice correct treatment models. Patra et al., (2017) showed that the cell line most sensitivite to trastuzumab is MDA-MB-453 with the PIK3CA. This findings are important which indicates the potential mechanism for trastuzumab resistance. Especially, HER-2 positive BCa cells were treated with combining trastuzumab with a PIK3CA inhibitor agent. A recent study reported that PIK3CA (E542K) were found to be significantly associated with reduced disease-free survival (DFS) in patients treated with trastuzumab (p: 0.018 and 0.005, respectively) (Singla et al., 2019). This study implied that PIK3CA genes are important biomarkers in HER2+ BCa. Also, the patients harboring mutant PIK3CA exhibit a poorer clinical outcome as compared to those carrying wild-type PIK3CA. PIK3CA mutation analysis can be usefully performed in real-life clinical practice (Cociolone et al., 2018). Investigation of the molecular mechanism of PIK3CA and its related genes is important

show abstract

Detection of PIK3CA Gene Mutations with HRM Analysis and Association with IGFBP-5 Expression Levels in Breast Cancer

Cited by 13 publications

References 51 publications

Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

Moderate Spectrum Genes Associated With Breast Cancer

BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Contact Info

Product

Resources

About